Ads
related to: movantik vs linzess
Search results
Results From The WOW.Com Content Network
Naloxegol (INN; PEGylated naloxol; [4] trade names Movantik and Moventig) is a peripherally acting μ-opioid receptor antagonist developed by AstraZeneca, licensed from Nektar Therapeutics, for the treatment of opioid-induced constipation. [5] It was approved in 2014 in adult patients with chronic, non-cancer pain. [6]
Peripherally acting μ-opioid receptor antagonists (PAMORAs) are a class of chemical compounds that are used to reverse adverse effects caused by opioids interacting with receptors outside the central nervous system (CNS), mainly those located in the gastrointestinal tract.
Plecanatide has been shown to be safe and effective. It has shown to be at least equally as effective as its main competitor, linaclotide (brand name Linzess), but has been shown to have a lower rate of diarrhea as an adverse drug reaction. [10]
Linaclotide, (sold under the brand name Linzess in the US and Mexico, and as Constella elsewhere) [6] is a drug used to treat irritable bowel syndrome with constipation and chronic constipation with no known cause.
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Methylnaltrexone (MNTX, brand name Relistor), used in form of methylnaltrexone bromide (INN, USAN, BAN), is a medication that acts as a peripherally acting μ-opioid receptor antagonist that acts to reverse some of the side effects of opioid drugs such as constipation without significantly affecting pain relief or precipitating withdrawals.
Ads
related to: movantik vs linzess